Skip Navigation



Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Neurology | Musculoskeletal | Family Medicine
Disease Category: Multiple Sclerosis
Location: United States, CO

Clinical Trial Details


Research Study Summary

New Investigational Medication for Relapsing Remitting Multiple Sclerosis (RRMS)


This is a 12 month open label study to evaluate the patient retention rate of Fingolimod vs. approved 1st-line disease modifying therapies in adults who are in early stages of treatment for RRMS.

Patient Inclusion Criteria:

  • 18-65
  • Patients naїve to treatment OR who have been treated with no more than one DMT; total treatment less than or equal to 5 years
  • For safety, certain cardiovascular conditions and medications are excluded; this will be reviewed with the study nurse

To Learn more

Both Male and Female


18 to 65 Years

Overall Status



12 Months

Facility Type



Alpine Clinical Research Center
1000 Alpine Avenue , Suite 200
Boulder, CO 80304
Phone: 303-443-7229

View Map

Research Center Information: Alpine Clinical Research Center

CW ID: 182094

Date Last Changed: July 18, 2013

DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.